MonoSolRx LLC Announces Successful Manufacturing Facility Audit For Oral Film Drug Production By The Australian Therapeutic Goods Administration

PORTAGE, Ind., Oct. 25 /PRNewswire/ -- MonoSolRx today announced that it has received a successful audit report for the manufacture of pharmaceuticals under the Australian Code of GMP of Medicinal Products (2002), from the Australian Therapeutic Goods Administration (the "TGA"). The audit report followed a visit to MonoSolRx's Portage based manufacturing facility, built to Class 100,000 standards.

MonoSolRx's Vice President for Pharmaceutical Development, Dr. Pradeep Sanghvi commented: "The successful audit result from the TGA speaks very well for our quality systems and follows on the heels of several successful big pharma audits. We have worked hard to deploy traditionally rooted, rigorous quality systems around our innovative film delivery system. This audit also speaks to our ability to supply product into various markets outside of the United States, including Europe and Asia."

MonoSolRx's President and Chief Executive Officer, P. Scott Bening observed: "Today's announcement signals the strength of our quality systems. Meeting and exceeding international regulatory requirements is a key component of our quality mandate."

About MonoSolRx LLC (www.monosolrx.com). MonoSolRx LLC is headquartered in Portage, Indiana. MonoSolRx is a leading drug delivery company that uses film as a fast-dissolve oral drug delivery platform. MonoSolRx previously acquired substantially all of the assets of Kosmos Pharma, including its extensive oral film intellectual property portfolio. MonoSolRx's FDTAB film oral dosage form looks like a postage stamp and dissolves readily on the tongue to deliver drugs to a patient, replacing the use of conventional tablets and capsules. MonoSolRx currently markets a variety of products together with its marketing partners.

CONTACT: Press, P. Scott Bening, +1-219-762-3165, or Fax, +1-219-764-4785,or Email, psbening@monosol.com, or Business Development Inquiries, JosephM. Fuisz, +1-703-999-7167, or Email, jfuisz@monosolrx.com, both ofMonoSolRx LLC

Web site: http://www.monosolrx.com//